Independent HCP preference analytics
Specialist clinical-case choices become a live intelligence layer for pharmaceutical teams.
Clinical Case
Second-line therapy choice
Drug Battle
Preference shift detected
Decision Profile
Oncology, metastatic NSCLC
Drug A
CPI Rating 1,742
Drug B
Momentum +8.6
Product Preview
VIALLMED turns HCP case choices into clean comparison views for brand, medical, and strategy teams.
See how each clinical-case vote moves CPI Rating and momentum against direct competitors.
Latest battle
Nucala +7.8
Closest rival
Dupixent -3.1
Shift source
Respiratory HCPs
Surface the clinical arguments changing physician confidence before the ranking fully moves.
Next question to test
Is safety hesitation concentrated in community practice, or already spreading across specialist centers?
Covered Companies
Tracking Real-time Clinical Shifts in Emerging Markets
